Lindhardsen J, Ahlehoff O, Gislason GH, Madsen OR, Olesen JB, Torp-Pedersen C, et al. The risk of myocardial infarction in rheumatoid arthritis and diabetes mellitus: a Danish nationwide cohort study. Ann Rheum Dis. 2011;70(6):929–34.

Article  PubMed  Google Scholar 

Polachek A, Touma Z, Anderson M, Eder L. Risk of cardiovascular morbidity in patients with psoriatic arthritis: a meta-analysis of observational studies. Arthritis Care Res (Hoboken). 2017;69(1):67–74.

Article  PubMed  Google Scholar 

Meng H, Lam SH, So H, Tam LS. Incidence and risk factors of major cardiovascular events in rheumatoid arthritis and psoriatic arthritis: a population-based cohort study. Semin Arthritis Rheum. 2024;65: 152416.

Article  CAS  PubMed  Google Scholar 

Bengtsson K, Forsblad-d’Elia H, Lie E, Klingberg E, Dehlin M, Exarchou S, et al. Are ankylosing spondylitis, psoriatic arthritis and undifferentiated spondyloarthritis associated with an increased risk of cardiovascular events? A prospective nationwide population-based cohort study. Arthritis Res Ther. 2017;19(1):1–12.

Article  Google Scholar 

Kerola AM, Kazemi A, Rollefstad S, Lillegraven S, Sexton J, Wibetoe G, et al. All-cause and cause-specific mortality in rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis: a nationwide registry study. Rheumatology. 2022;61:4656–66.

Article  PubMed  PubMed Central  Google Scholar 

Crowson CS, Rollefstad S, Ikdahl E, Kitas GD, Van Riel PL, Gabriel SE, et al. Impact of risk factors associated with cardiovascular outcomes in patients with rheumatoid arthritis. Ann Rheum Dis. 2018;77(1):48–54.

Article  CAS  PubMed  Google Scholar 

Zhang X, Wu H, Fan B, Shi M, Lau ES, Yang A, et al. Lifetime risk of developing diabetes in Chinese people with normoglycemia or prediabetes: a modeling study. PLoS Med. 2022;19(7): e1004045.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Toft-Nielsen M-B, Damholt MB, Madsbad S, Hilsted LM, Hughes TE, Michelsen BK, et al. Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients. J Clin Endocrinol Metab. 2001;86(8):3717–23.

Article  CAS  PubMed  Google Scholar 

Kanat M, DeFronzo RA, Abdul-Ghani MA. Treatment of prediabetes. World J Diabetes. 2015;6(12):1207.

Article  PubMed  PubMed Central  Google Scholar 

Brannick B, Dagogo-Jack S. Prediabetes and cardiovascular disease: pathophysiology and interventions for prevention and risk reduction. Endocrinol Metab Clin. 2018;47(1):33–50.

Article  Google Scholar 

Cai X, Zhang Y, Li M, Wu JH, Mai L, Li J, et al. Association between prediabetes and risk of all cause mortality and cardiovascular disease: updated meta-analysis. BMJ. 2020;370:m2297.

Article  PubMed  PubMed Central  Google Scholar 

Vieira R, Souto SB, Sánchez-López E, López Machado A, Severino P, Jose S, et al. Sugar-lowering drugs for type 2 diabetes mellitus and metabolic syndrome—Review of classical and new compounds: part-I. Pharmaceuticals. 2019;12(4):152.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Patti AM, Rizvi AA, Giglio RV, Stoian AP, Ligi D, Mannello F. Impact of glucose-lowering medications on cardiovascular and metabolic risk in type 2 diabetes. J Clin Med. 2020;9(4):912.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Roumie CL, Chipman J, Min JY, Hackstadt AJ, Hung AM, Greevy RA, et al. Association of treatment with metformin vs sulfonylurea with major adverse cardiovascular events among patients with diabetes and reduced kidney function. JAMA. 2019;322(12):1167–77.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tanaka A, Sata M, Okada Y, Teragawa H, Eguchi K, Shimabukuro M, et al. Effect of ipragliflozin on carotid intima-media thickness in patients with type 2 diabetes: a multicenter, randomized, controlled trial. Eur Heart J Cardiovasc Pharmacother. 2023;9(2):165–72.

Article  PubMed  Google Scholar 

Masson W, Lavalle-Cobo A, Lobo M, Masson G, Molinero G. Novel antidiabetic drugs and risk of cardiovascular events in patients without baseline metformin use: a meta-analysis. Eur J Prev Cardiol. 2021;28(1):69–75.

Article  PubMed  Google Scholar 

Phung O, Schwartzman E, Allen R, Engel S, Rajpathak S. Sulphonylureas and risk of cardiovascular disease: systematic review and meta-analysis. Diabet Med. 2013;30(10):1160–71.

Article  CAS  PubMed  Google Scholar 

Abdelmoneim A, Eurich D, Light P, Senior P, Seubert J, Makowsky M, et al. Cardiovascular safety of sulphonylureas: over 40 years of continuous controversy without an answer. Diabetes Obes Metab. 2015;17(6):523–32.

Article  CAS  PubMed  Google Scholar 

Gamble J-M, Chibrikov E, Twells LK, Midodzi WK, Young SW, MacDonald D, et al. Association of insulin dosage with mortality or major adverse cardiovascular events: a retrospective cohort study. Lancet Diabetes Endocrinol. 2017;5(1):43–52.

Article  CAS  PubMed  Google Scholar 

Rados DV, Falcetta MRR, Pinto LC, Leitao CB, Gross JL. All-cause mortality and cardiovascular safety of basal insulin treatment in patients with type 2 diabetes mellitus: a systematic review with meta-analysis and trial sequential analysis. Diabetes Res Clin Pract. 2021;173: 108688.

Article  CAS  PubMed  Google Scholar 

Group UPDS. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352(9131):837–53.

Article  Google Scholar 

Wong GLH, Hui VWK, Tan Q, Xu J, Lee HW, Yip TCF, et al. Novel machine learning models outperform risk scores in predicting hepatocellular carcinoma in patients with chronic viral hepatitis. JHEP Rep. 2022;4(3): 100441.

Article  PubMed  PubMed Central  Google Scholar 

So H, Lam TO, Meng H, Lam SHM, Tam L-S. Time and dose-dependent effect of systemic glucocorticoids on major adverse cardiovascular event in patients with rheumatoid arthritis: a population-based study. Ann Rheum Dis. 2023;82(11):1387–93.

Article  CAS  PubMed  Google Scholar 

Genuth S, Alberti K, Bennett P, Buse J, DeFronzo R, Kahn R, et al. Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care. 2003;26(11):3160–8.

Article  PubMed  Google Scholar 

Dobiasova M. AIP–atherogenic index of plasma as a significant predictor of cardiovascular risk: from research to practice. Vnitr Lek. 2006;52(1):64–71.

CAS  PubMed  Google Scholar 

Ruscitti P, Ursini F, Cipriani P, Ciccia F, Liakouli V, Carubbi F, et al. Prevalence of type 2 diabetes and impaired fasting glucose in patients affected by rheumatoid arthritis: results from a cross-sectional study. Medicine. 2017;96(34): e7896.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Dal Bello G, Gisondi P, Idolazzi L, Girolomoni G. Psoriatic arthritis and diabetes mellitus: a narrative review. Rheumatol Ther. 2020;7:271–85.

Article  Google Scholar 

Medina-Leyte DJ, Zepeda-García O, Domínguez-Pérez M, González-Garrido A, Villarreal-Molina T, Jacobo-Albavera L. Endothelial dysfunction, inflammation and coronary artery disease: potential biomarkers and promising therapeutical approaches. Int J Mol Sci. 2021;22(8):3850.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Huang Z, Chen C, Li S, Kong F, Shan P, Huang W. Serum markers of endothelial dysfunction and inflammation increase in hypertension with prediabetes mellitus. Genet Test Mol Biomark. 2016;20(6):322–7.

Article  CAS  Google Scholar 

Zhang X, Wu H, Fan B, Shi M, Lau ES, Yang A, et al. The role of age on the risk relationship between prediabetes and major morbidities and mortality: analysis of the Hong Kong diabetes surveillance database of 2 million Chinese adults. Lancet Reg Health West Pac. 2022;30:100599. https://doi.org/10.1016/j.lanwpc.2022.100599.

Article  PubMed  PubMed Central  Google Scholar 

Baghdadi LR, Woodman RJ, Shanahan EM, Mangoni AA. The impact of traditional cardiovascular risk factors on cardiovascular outcomes in patients with rheumatoid arthritis: a systematic review and meta-analysis. PLoS ONE. 2015;10(2): e0117952.

Article  PubMed